Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab Long-Term Extension in Axial Spondyloarthritis
NCT03129100Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2017
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of ixekizumab in axial spondyloarthritis (axSpA), sponsored by Eli Lilly and Company. Started May 2017; status: completed.
02
Drugs
ixekizumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT03129100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03129100.